Rapid drug access and scientific rigour: a delicate balance.

The Lancet Neurology

The Lancet Neurology.

Lancet Neurol ; 20(1): 1, 2021 01.

Article in English | MEDLINE | ID: covidwho-978051

Subject(s)

Alzheimer Disease/drug therapy; Amyloid beta-Peptides/immunology; Antibodies, Monoclonal, Humanized/pharmacology; Biomedical Research/standards; Clinical Trials as Topic/standards; Drug Approval; Research Design/standards; Antibodies, Monoclonal, Humanized/administration & dosage; Antibodies, Monoclonal, Humanized/adverse effects; Drug Approval/legislation & jurisprudence; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Research Design / Clinical Trials as Topic / Amyloid beta-Peptides / Drug Approval / Biomedical Research / Alzheimer Disease / Antibodies, Monoclonal, Humanized Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Lancet Neurol Journal subject: Neurology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google